Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

Share Price is delayed by 15 minutes
Get Live Data
12.75    0.50 (4.08%)
Bid:
12.50
Ask:
13.00
Spread: 0.50 (4.00%)
Market Cap: £32.01m
ABDX Live PriceLast checked at - London Stock Exchange

Intraday Abingdon Healt. Share Chart

TR-1

19 Aug 2024 13:45

RNS Number : 9686A
Abingdon Health PLC
19 August 2024
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

ABINGDON HEALTH PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

14 AUGUST 2024

6. Date on which issuer notified (DD/MM/YYYY):

16 AUGUST 2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

9.8679

9.8679

18,702,013

Position of previous notification (if

applicable)

N/A

N/A

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BLF79J41

18,702,013

9.8679

SUBTOTAL 8. A

18,702,013

9.8679

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Canaccord Genuity Group Inc.

9.8679

9.8679

 

Canaccord Genuity Wealth Group Holdings Limited

9.8679

9.8679

 

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

9.8679

9.8679

 

Canaccord Genuity Wealth Group Limited

9.8679

9.8679

 

Canaccord Genuity Asset Management Limited

9.8679

9.8679

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

The change in the percentage of shares held is due entirely to participation in the placing by Abingdon Health plc, the shares from which were admitted to trading on AIM on 14/08/2024.

 

 

Place of completion

BLACKPOOL, ENGLAND

Date of completion

19 AUGUST 2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFSFTSIALIS
Date   Source Headline
29th May 20267:00 amRNS-RPresentation at Mello2026
27th May 20267:00 amRNSUS tax credit agreement
19th May 20267:00 amRNSEarn-out Consideration and Issue of Equity
11th May 20267:00 amRNS-RLaunch of LVOne Stroke Test by UpFront Diagnostics
7th May 20265:38 pmRNSHolding(s) in Company
6th May 20267:00 amRNS-RUpdate on Partnership with 4TEEN4 Pharmaceuticals
21st Apr 20267:00 amRNSAdmission to trading on OTCQB in the US
15th Apr 20267:00 amRNSEMI Share Option Scheme
14th Apr 20267:00 amRNSTrading to commence on the OTCQB in the US
30th Mar 20267:00 amRNS£4.8m contracts awarded
17th Mar 20267:00 amRNSHalf-year Financial Report
17th Mar 20267:00 amRNSHalf-year Financial Report
12th Mar 20267:00 amRNS$2.5m Contract for clinical self-test development
10th Mar 20267:00 amRNSTrading on the OTCQB Venture Market in the US
5th Mar 20267:00 amRNSNotice of Results
15th Jan 20267:01 amRNSTrading Update
15th Jan 20267:00 amRNSAppointment of NOMAD & Corporate Broker
29th Dec 20252:35 pmRNSExercise of options and total voting rights
29th Dec 20252:35 pmRNSExercise of options and total voting rights
18th Dec 20257:00 amRNS-REuropean patent for AppDx® smartphone reader
10th Dec 20251:47 pmRNSResult of Annual General Meeting
4th Dec 20257:00 amRNSVesting and Award of Options under LTIP
2nd Dec 20253:08 pmRNSHolding(s) in Company
14th Nov 20252:00 pmRNSNotice of AGM & Publication of 2025 Annual Report
11th Nov 20257:00 amRNSFinal Results
10th Nov 20257:00 amRNSc.US$2m multiplex diagnostic test contract win
6th Nov 20257:00 amRNSLaunch of seaweed-based lateral flow housings
4th Nov 20254:58 pmRNSHolding(s) in Company
4th Nov 20257:00 amRNSHolding(s) in Company
3rd Nov 20257:00 amRNSNotice of Results
30th Oct 20259:43 amRNSResult of Meeting and TVR
17th Oct 20257:00 amRNSResult of Retail Offer
14th Oct 20257:58 amRNSLaunch of Retail Offer
14th Oct 20257:47 amRNSResult of Placing and Notice of GM
13th Oct 20255:04 pmRNSProposed Placing and Retail Offer
1st Sep 20257:00 amRNSUS CDMO Operations Update
14th Aug 20256:01 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSTrading update
31st Jul 20257:00 amRNSc. US$2.5m companion diagnostic test contract win
12th Jun 20257:00 amRNS€2m contract win for companion diagnostic test
4th Jun 20257:00 amRNS-RUpdate re. strategic partnership with FOFH
2nd Jun 20257:00 amRNS-RAvian flu (H5N1) lateral flow test
2nd May 202512:00 pmRNSAward of Options under LTIP
24th Mar 20257:00 amRNSDirectorate Changes
24th Mar 20257:00 amRNSHalf-year Report
17th Mar 20257:00 amRNSNotice of Results
17th Mar 20257:00 amRNSSalistick™ to be launched in Germany
27th Jan 20257:00 amRNSFunding award to develop test for malaria parasite
19th Dec 20247:00 amRNSDirectorate Change
17th Dec 20247:09 amRNSAbingdon Analytical Laboratory opens at Doncaster

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.